---
title: "Otezla (apremilast), all indications: Specific populations questions"
description: "Specific populations questions on Otezla (apremilast) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Does Otezla need a dose adjustment for kidney impairment? Can Otezla XR be used in severe kidney impairment? Does Otezla need a dose adjustment for liver impairment? Can Otezla be used during pregnancy? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/otezla/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Otezla (apremilast), all indications: Specific populations questions

Manufacturer: Amgen Inc.  
Prescribing information: [Otezla](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis)

## Specific populations

<a id="otezla-kidney-dosing"></a>

### Does Otezla need a dose adjustment for kidney impairment?

> “OTEZLA pharmacokinetics were characterized in adult subjects with mild, moderate, and severe renal 
> impairment as defined by a creatinine clearance of 60-89, 30-59, and less than 30 mL per minute,”

Source: [OTEZLA: Prescribing information, page 15, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=15)

> “respectively, by the Cockcroft–Gault equation. No dosage adjustment is needed in patients with mild or 
> moderate renal impairment. In adult patients with severe renal impairment, reduce the maintenance 
> dosage to OTEZLA 30 mg once daily. In pediatric patients 6 years of age and older and weighing at least 
> 20 kg with psoriatic arthritis or moderate to severe plaque psoriasis and severe renal impairment, reduce 
> the maintenance dosage to OTEZLA 30 mg once daily for pediatric patients weighing at least 50 kg and 
> to OTEZLA 20 mg once daily for pediatric patients weighing 20 kg to less than 50 kg [see Dosage and 
> Administration (2.3) and Clinical Pharmacology (12.3)].”

Source: [OTEZLA: Prescribing information, page 16, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=16)

> “For initial dosage titration in adult patients with severe renal impairment (creatinine clearance [CLcr] of 
> less than 30 mL per minute estimated by the Cockcroft–Gault equation), titrate OTEZLA using only the 
> AM schedule listed in Table 1 and skip the PM doses. The recommended maintenance dosage in this 
> group is OTEZLA 30 mg once daily [see Use in Specific Populations (8.6) and Clinical Pharmacology 
> (12.3)].”

Source: [OTEZLA: Prescribing information, page 5, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=5)

Note: The 8.6 Renal Impairment passage continues from page 15 to page 16 of the Prescribing Information.

<a id="otezla-xr-kidney"></a>

### Can Otezla XR be used in severe kidney impairment?

> “OTEZLA XR is not recommended for adult patients with severe renal impairment; the appropriate dosage 
> for these patients has not been determined [see Use in Specific Populations (8.6) and Clinical 
> Pharmacology (12.3)].”

Source: [OTEZLA: Prescribing information, page 5, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=5)

> “OTEZLA XR is not recommended for pediatric patients with severe renal impairment; the appropriate 
> dosage for these patients has not been determined [see Use in Specific Populations (8.6) and Clinical 
> Pharmacology (12.3)].”

Source: [OTEZLA: Prescribing information, page 5, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=5)

> “The pharmacokinetics of OTEZLA XR has not been evaluated in patients with renal impairment. In 
> patients with severe renal impairment, it is recommended that  OTEZLA be used instead of OTEZLA XR 
> [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].”

Source: [OTEZLA: Prescribing information, page 16, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=16)

<a id="otezla-liver-dosing"></a>

### Does Otezla need a dose adjustment for liver impairment?

> “Apremilast pharmacokinetics were characterized in subjects with moderate (Child Pugh B) and severe 
> (Child Pugh C) hepatic impairment. No dosage adjustment is necessary in these patients.”

Source: [OTEZLA: Prescribing information, page 16, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=16)

> “Patients with Hepatic Impairment: The pharmacokinetics of apremilast is not affected by moderate or 
> severe hepatic impairment.”

Source: [OTEZLA: Prescribing information, page 18, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=18)

## Pregnancy and breastfeeding

<a id="otezla-pregnancy"></a>

### Can Otezla be used during pregnancy?

> “Available data with OTEZLA use in pregnant women have not identified a drug-associated risk of major 
> birth defects or adverse maternal or fetal outcomes (see Data).”

Source: [OTEZLA: Prescribing information, page 12, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=12)

> “Based on findings from animal reproduction studies, OTEZLA/OTEZLA XR may increase the 
> risk for fetal loss (see Data).  Advise pregnant women of the potential risk of fetal loss.”

Source: [OTEZLA: Prescribing information, page 13, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=13)

> “A pregnancy registry conducted by the Organization of Teratology Information Specialists (OTIS) in the 
> United States and Canada assessed the risk of major birth defects in liveborn infants of women with 
> psoriatic arthritis, psoriasis, or Behçet’s Disease exposed to apremilast in the first trimester. The study 
> compared pregnant women treated with apremilast (n = 15) with disease matched pregnant women who 
> were not exposed to apremilast (n = 106). In the apremilast-exposed cohort, there were no reports of 
> liveborn infants with major birth defects nor miscarriages. One stillbirth was reported in the apremilast 
> exposed cohort.  These data are limited by the small sample size of apremilast-exposed pregnancies.”

Source: [OTEZLA: Prescribing information, page 13, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=13)

<a id="otezla-breastfeeding"></a>

### Can Otezla be used while breastfeeding?

> “There are no data on the presence of apremilast in human milk, its effects on the breastfed infant, or its 
> effects on milk production. However, apremilast was detected in the milk of lactating mice (see Data). 
> When a drug is present in animal milk, it is likely that the drug will be present in human milk. The 
> developmental and health benefits of breastfeeding should be considered along with the mother’s clinical 
> need for OTEZLA/OTEZLA XR and any potential adverse effects on the breastfed infant from 
> OTEZLA/OTEZLA XR or from the underlying maternal condition.”

Source: [OTEZLA: Prescribing information, page 14, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=14)

## Related pages
- [Medical information: Otezla (apremilast): All indications](https://www.evicenter.com/medical-information/otezla)
- [Indication](https://www.evicenter.com/medical-information/otezla/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/otezla/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/otezla/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/otezla/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/otezla/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/otezla/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/otezla/access-and-coverage)
